Introduction

Biologics have transformed care for several allergic and inflammatory airway diseases. For allergic rhinitis (AR), however, their role is narrow. This page explains where biologics can help, when they usually don’t, and why allergen immunotherapy (AIT) remains the disease‑modifying mainstay for seasonal and perennial AR. Note: Wyndly does not prescribe biologics; our focus is testing and immunotherapy education and care.> Sidebar — Where biologics fit (at a glance)

• Primary use: add-on therapy for moderate–to–severe asthma or chronic rhinosinusitis with nasal polyps (CRSwNP) that remain uncontrolled on guideline‑directed care.
• Not first‑line for isolated allergic rhinitis (seasonal or perennial) without severe asthma/CRSwNP.
• Access: typically requires specialist evaluation plus U.S. payer prior authorization; step‑therapy and documentation of severity/control are common.
• Monitoring: office‑based initiation/onboarding and ongoing assessments per label and specialist.
• Cost: generally high; patients should review coverage, co‑insurance, and authorization timelines with their plan.
• Disease modification for AR: consider allergen immunotherapy when symptoms persist despite medications/avoidance — see our immunotherapy page.
• Planning your season: for local pollen timing and triggers, see state guides such as California and Oregon.

What we mean by “biologics” in airway/allergy care

Biologics are targeted monoclonal antibodies directed at pathways that drive type‑2 (Th2) inflammation.

• Anti‑IgE: omalizumab

• Anti‑IL‑4Rα (blocks IL‑4/IL‑13): dupilumab

• Anti‑IL‑5/IL‑5R: mepolizumab, benralizumab, reslizumab

• Anti‑TSLP: tezepelumab These agents are FDA‑approved for conditions like moderate‑to‑severe asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), atopic dermatitis, and chronic spontaneous urticaria. None is broadly approved solely for uncomplicated AR; any AR benefit is typically indirect (e.g., via control of comorbid asthma or polyps) and requires specialist management.

Where biologics can fit for patients who also have AR

Biologics may be considered by a specialist when AR coexists with—and is clinically dominated by—another approved indication:

• Moderate‑to‑severe allergic or eosinophilic asthma that remains uncontrolled on guideline‑directed therapy (e.g., high‑dose inhaled corticosteroids plus additional controllers). Improved asthma control can reduce overall upper‑airway symptom burden.

• CRSwNP with significant obstruction, smell loss, or recurrent need for systemic corticosteroids or surgery. Biologics that shrink nasal polyps often improve upper‑airway symptoms that overlap with AR.

• Chronic spontaneous urticaria (anti‑IgE) where pruritus and wheals are the primary driver of impairment; AR symptom spillover may still require AR‑specific therapy.

Where biologics generally don’t fit

For isolated seasonal or perennial AR without severe asthma or CRSwNP, biologics are rarely first‑line because:

• Evidence: High‑quality disease‑modifying data for AR alone are strongest for AIT (shots or sublingual), not biologics.

• Access and cost: Biologics require injections, safety monitoring, and insurance authorization; annual costs are typically orders of magnitude higher than guideline AR care.

• Stepwise care works for most: Environmental control, intranasal corticosteroids, intranasal/oral antihistamines, and AIT address the vast majority of AR.

Why most AR care still relies on allergen immunotherapy (AIT)

AIT retrains the immune system against the exact allergens that trigger AR, providing durable benefit after therapy ends.

• Disease modification: Gradual desensitization reduces reactivity to pollen, dust mites, pets, and molds.

• Durability: Benefits persist for years after completing a typical 3‑year course.

• Safety and convenience: Sublingual options enable at‑home dosing with a favorable safety profile.

• Multi‑allergen tailoring: Dosing profiles are personalized to the patient’s sensitizations. Learn more about Wyndly’s approach to at‑home, physician‑directed AIT on our immunotherapy page.

Quick comparison: biologics vs immunotherapy for AR‑dominant patients

Dimension	Biologics (anti‑IgE / anti‑IL‑4/13 / anti‑IL‑5 / anti‑TSLP)	Allergen immunotherapy (AIT)
Primary aim	Suppress/type‑2 pathway modulation (systemic)	Desensitize to specific allergens (disease‑modifying)
Typical use in AR	With severe comorbid asthma/CRSwNP; not routine for AR alone	First disease‑modifying option when meds/avoidance are insufficient
Route/setting	Subcutaneous injections; clinic onboarding and monitoring	Sublingual (home) or subcutaneous (clinic)
Duration	Long‑term while benefits needed	Time‑limited (often ~3 years) with lasting benefit
Cost/coverage	High; prior authorization common	Generally lower total cost; sublingual tablets/drops vary by plan

Practical stepwise pathway for AR

1) Confirm triggers and seasonality: Use validated testing to identify pollen/pet/dust/mold sensitivities. If you need daily local pollen tracking, use Wyndly’s pollen data. 2) Optimize foundational therapy: Environmental control; intranasal steroids; intranasal/oral antihistamines; short‑course add‑ons (e.g., anticholinergic sprays for rhinorrhea) as needed. 3) Add disease modification when symptoms persist: Discuss AIT (sublingual or subcutaneous). See our overview of allergy immunotherapy. 4) Reserve biologics for the right scenarios: If moderate‑to‑severe asthma or CRSwNP co‑drives overall disease burden and remains uncontrolled after guideline therapy—and you meet label and payer criteria—an allergy/ENT specialist may consider a biologic. AR‑specific triggers often still benefit from AIT in parallel or subsequently.

Safety, access, and monitoring considerations (biologics)

• Specialist care only: Patient selection, baseline labs, and longitudinal response assessment are essential.

• Injections and follow‑up: Most agents require office‑based initiation and regular dosing intervals.

• Adverse effects: Conjunctivitis/eye symptoms (with some IL‑4/13 blockade), injection‑site reactions, transient eosinophilia, and rare hypersensitivity reactions; asthma biologics also require adherence to controller therapy.

• Cost/coverage: Prior authorization, step‑therapy, and documentation of severity/control are typical payer requirements in the U.S.

Key takeaways

• For most people whose primary problem is allergic rhinitis, AIT is the disease‑modifying therapy with the strongest track record and most practical risk‑benefit profile.

• Biologics are valuable tools for the right patient—but usually because of severe comorbid asthma or CRSwNP, not uncomplicated seasonal AR.

• Wyndly focuses on accurate trigger identification, education, and physician‑directed immunotherapy for long‑term relief; we do not offer biologics.

Explore Wyndly resources

• Allergy immunotherapy explained: Sublingual and shot‑based options

• Daily pollen levels where you live: Pollen data

• State and season guides to plan your year: Start at our Learning Center and location pages from the Wyndly site.